Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery is a phase 2/3, randomised interventional study registered as NCT03051464 by Sir Mortimer B. Davis - Jewish General Hospital, with a registry enrolment figure of 131 participants, started 2017-04-25 and due to reach its primary completion in 2028-01. Interventions recorded: Complete responders and Non-complete responders; Chemoradiation + EBRT Boost; Chemoradiation + HDRBT Boost. Conditions listed: Stage II Rectal Cancer; Organ Preservation; Non-operative Treatment; Rectal Cancer (Stage III); Rectal Cancer Patients. Primary outcome: TME-free survival. Colorectal eligibility wording from the registry: "* Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic/trans-rectal ultrasound". Sites: Canada, United States. No results are recorded here; the registry entry is the source.